• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Different Methods of Contraception and Their Impact on Severity and Incidence of Acne

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Combined oral contraceptives (OCs) are used to treat acne
    • OCs with drospirenone appear to be particularly effective
  • Some studies suggest that progestin-only methods may results in additional cases of acne vs combined OCs
  • Barbieri et al. (Obstetrics & Gynecology, 2020) examined different contraceptive methods and their effects on incidence and severity of acne

METHODS:

  • Retrospective cohort study
  • Participants
    • Women 12 to 40 years of age
    • Within first year after initiation of contraception
  • Study design
    • Data source: Deidentified commercial claims database
    • Acne severity: Subgroup analysis among a patient cohort with a history of acne
  • Primary outcome
    • Acne incidence: No prior history
    • Acne severity: Prior history of acne: Incidence of treatment escalation from topical to oral tetracycline-class antibiotic

RESULTS:

  • 336,738 women met criteria
    • Combined OCs (82.9%) | Levonorgestrel IUDs (10.6%) | Copper IUD (2.1%) | Etonogestrel implant (1.9%) | Progestin-only OC (1.3%) | DMPA injection (1.2%)
  • Compared with combined OCs, the following were associated with an increased risk of clinical encounters with acne  
    • Copper IUD
      • Hazard ratio (HR) 1.14 (95% CI, 1.01 to 1.29)
    • Levonorgestrel IUD
      • HR 1.09 (95% CI, 1.03 to 1.16)
  • Women who switched from OCs to another method were more likely to have clinical encounters for acne
    • Progestin-only OCs: adjusted HR 1.70 (95% CI, 1.23–2.35)
    • Levonorgestrel IUDs: adjusted HR 1.93 (95% CI, 1.69–2.22)
    • Etonogestrel implant: adjusted HR 1.45 (95% CI, 1.08–1.95)
    • Copper IUD: adjusted HR 1.70 (95% CI, 1.23–2.35)
  • History of acne: 21,178 women
    • Compared with OCs, the following were associated with an increased risk of treatment escalation from topical acne medications to an oral tetracycline class antibiotic
    • Copper IUD
      • HR 1.44 (95% CI, 1.00 to 2.06)
    • Levonorgestrel IUD
      • HR 1.34 (95% CI, 1.10 to 1.64)

CONCLUSION:

  • The authors point out that absolute differences between contraceptive methods and incidence of clinical acne encounters were small (<1%)
  • Furthermore, the authors state that

…some of the observed associations in other studies between noncombined OC contraception classes and acne may be due to prior discontinuation of combined OCs before starting the noncombined OC contraception method, and that overall, large differences in the risk of acne between contraceptive classes are unlikely

Learn more – Primary Sources:

Influence of Contraception Class on Incidence and Severity of Acne Vulgaris


Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Is Progestin-Based Contraception Linked to Depression?
Practical info for your gynecology practice
Hormonal Contraception Benefits – Beyond Pregnancy Prevention
Phase 3 Trial: IUD Efficacy and Safety at 5 Years 

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site